Georgia Research Alliance

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Urjanet, Inc. is a company that specializes in providing a cloud-based platform for automated access to utility data. Founded in 2009 and headquartered in Atlanta, Georgia, with an additional location in Chennai, India, Urjanet connects directly to utility providers to acquire and normalize utility bills and interval data. Its offerings include automated access to utility bill data across various utilities, granular measurements of energy consumption, and advanced metering infrastructure data without requiring additional hardware or software. The platform also features capabilities for weather data analysis and alerts for billing and consumption anomalies. Urjanet's solutions are designed to improve business intelligence, energy management, accounting, and procurement processes for organizations, enabling them to enhance financial performance, energy efficiency, and sustainability.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

LymphaTech is a healthcare technology company focused on diagnosing, monitoring, and preventing lymphedema through 3D body scanning. Its mobile platform uses proprietary algorithms to accurately measure limb geometry and track volume changes over time, enabling doctors and physical therapists to diagnose lymphedema earlier and tailor targeted treatments, with scans that can be performed at home or in the clinic. Founded in 2014 and based in Atlanta, Georgia, LymphaTech aims to improve quality of life for patients, including breast cancer survivors, by providing timely detection and ongoing management of the condition.

Whisper Communications is an Atlanta-based company that specializes in wireless networking services, leveraging innovative technologies to enhance data security. Utilizing patent-pending technology developed at the Georgia Institute of Technology, Whisper has created an encoding methodology that ensures data signals transmitted beyond a designated area, referred to as the "cone of silence," are rendered useless to eavesdroppers. The company's approach focuses on physical layer security, where the safety of data is intrinsically linked to its proximity to the data source. This enables IT companies to effectively monitor, track, and control devices located within a fixed area, thereby enhancing the overall security of wireless communications.